 |
Top Story
Pharma Caught in Political Crosshairs
It has become open season on pharmaceutical companies, as Congressional committees ramp up industry oversight and political candidates on all sides look to win points by attacking drug pricing and marketing. Jill Wechsler reports
...Read more |
 |
Advertising
4A's Partner Award Pushes Healthcare Agencies into the Spotlight
Slowly but surely healthcare agencies are being given a place at the table at ad industry’s top award shows. And while not close enough to rub elbows with the Don Drapers and Peggy Olsons of the ad world, at least they’re being invited. Marylyn Donahue reports
...Read more |
 |
Strategy
Tech Giants Collaborate and Disrupt in Life Sciences Industry
As tech giants, enter the life sciences industry, healthcare companies should adapt their business model and embark with these new players on a more ambitious, personalized, and preventive healthcare strategy, writes Anaïs Frappé
...Read more |
 |
Marketing
Seeing Through the Physician’s Eyes: Three Marketing Priorities for Pharma
Physicians who show true empathy for their patients tend to have better outcomes. Their patients stick to treatment plans, heal faster, and have fewer hospital readmissions. The same principle applies to pharma companies trying to market to physicians, write Pratap Khedkar and Malcolm Sturgis.
...Read more |
Europe
Drug Pricing in Europe: A Discordant Bandwagon
The Parliamentary Assembly of the Council of Europe is the latest to clamber aboard the well-filled bandwagon now rumbling and rattling across Europe in an increasingly noisy debate over drug prices. Reflector reports
...Read more |
Europe
Europe Under Pressure: Gearing Up for a Year of Regulatory Convergence
In the last year European regulatory authorities sharpened their focus on gathering more data and on achieving transparency and harmonization. Erick Gaussens reviews 2015 and looks at companies’ need to respond to converging demands in 2016
...Read more |
Special Feature
Pharm Exec's Pipeline Report 2016
Will a drug pipeline harvest full of treatments founded on strong science, supportive regulation, and unmet medical need offer solace to shareholders and the promise of a reputational rebound? Will presidential politics add to the pressures on drug pricing, with a sour coda to the old refrain, "in the US, the market decides?" Casey McDonald reports
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology - Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
 Learn more |
 |
 // Heat Biologics (Durham, NC) appointed Timothy Creech as its new Chief Financial Officer.
// Sunshine Heart’s (Eden Prairie, MN) Chief Executive Officer, David A. Rosa left the company on November 30, 2015. John L. Erb, Chairman of the Board of Directors, has been named Interim Chief Executive Officer and President and will continue to serve as Chairman of the Board.
// Chiasma (Newton, MA)announced that James R. Tobin and John F. Thero have joined the company's Board of Directors.
// RedHill Biopharma (Tel-Aviv, Israel) announced the passing of Alicia Rotbard. Ms. Rotbard joined the company’s Board of Directors in May 2011 and served as Chairman of the Company's Audit Committee and a member of its Compensation Committee. // |
|
|
|
|
